Literature DB >> 21467929

Calcium channel blockers and modulation of innate immunity.

Wenling Liu1, Akira Matsumori.   

Abstract

PURPOSE OF REVIEW: Researchers and physicians are gaining more understanding of the utility of calcium channel blockers (CCBs) especially in modulation of innate immunity, and choose suitable ones in clinical practice. This review summarizes the recent related research findings. RECENT
FINDINGS: Sustained and/or dysregulated expression of pro-inflammatory cytokines is sufficient to produce tissue injury and provoke overt cardiac decompensation. The important question that remains to be addressed is whether or not it will be possible to modulate the inappropriate or maladaptive consequences of innate immune activation and pro-inflammatory cytokine expression in the mammalian heart. CCBs, such as nifedipine, amlodipine, diltiazem, and verapamil, promote the relaxation of cardiac and smooth muscle cells by inhibiting calcium influx through calcium channels and calcium release from intracellular stores, and are commonly used in the treatment of cardiovascular disorders. Recently, several in-vitro studies have shown that, besides the effects they exert on muscle cells, CCBs also suppress the activation of various participants in immune reactions, including T cells, mast cells and macrophages, suggesting that they can be immunosuppressant.
SUMMARY: CCBs maybe suppress the activation of various participants in immune reactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467929     DOI: 10.1097/QCO.0b013e3283463e5b

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  13 in total

1.  Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study.

Authors:  Farsad Afshinnia; Karen Belanger; Paul M Palevsky; Eric W Young
Journal:  Ren Fail       Date:  2013-09-02       Impact factor: 2.606

2.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

Review 3.  Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.

Authors:  Itsuro Kazama
Journal:  J Physiol Sci       Date:  2014-08-06       Impact factor: 2.781

4.  Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.

Authors:  Anniina Koski; Mari Raki; Petri Nokisalmi; Ilkka Liikanen; Lotta Kangasniemi; Timo Joensuu; Anna Kanerva; Sari Pesonen; Ramon Alemany; Akseli Hemminki
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

5.  Lessons learned from experimental myocarditis.

Authors:  A Matsumori
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

6.  Effect of nifedipine, a calcium channel blocker, on the generation of nitric oxide and interleukin-1β by murine macrophages activated by lipopolysaccharide from Prevotella intermedia.

Authors:  So-Hui Choe; Eun-Young Choi; Jin-Yi Hyeon; Bo Ram Keum; In Soon Choi; Sung-Jo Kim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-08-11       Impact factor: 3.000

7.  The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.

Authors:  Kevin Wilhelmsen; Samira Khakpour; Alphonso Tran; Kayla Sheehan; Mark Schumacher; Fengyun Xu; Judith Hellman
Journal:  J Biol Chem       Date:  2014-03-18       Impact factor: 5.157

8.  Adaptive Membrane Fluidity Modulation: A Feedback Regulated Homeostatic System and Target for Pharmacological Intervention.

Authors:  Elzbieta Izbicka; Robert T Streeper; Christopher Louden
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

9.  Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.

Authors:  Xiuman Zhou; Ling Jiao; Yuzhen Qian; Qingyu Dong; Yixuan Sun; Wei V Zheng; Wenshan Zhao; Wenjie Zhai; Lu Qiu; Yahong Wu; Hongfei Wang; Yanfeng Gao; Junhui Chen
Journal:  Biomolecules       Date:  2021-05-10

10.  Diltiazem reduces mortality and breakdown of ATP in red blood cell induced by isoproterenol in a freely moving rat model in vivo.

Authors:  Pollen K F Yeung; Zhaolin Xu; Dena Seeto
Journal:  Metabolites       Date:  2014-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.